Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective. | Value Health;17(7): A343, 2014 Nov. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective.

Charokopou, M; Vioix, H; Verheggen, B G; Dillon, S; Franks, D.

Affiliation

Charokopou M; Pharmerit International, Rotterdam, The Netherlands.
Vioix H; AstraZeneca UK Ltd., Luton, UK.
Verheggen BG; Pharmerit International, Rotterdam, The Netherlands.
Dillon S; AstraZeneca UK Ltd., Luton, UK.
Franks D; AstraZeneca UK Ltd., Luton, UK.

Value Health ; 17(7): A343, 2014 Nov.

Article in En | MEDLINE | ID: mdl-27200640

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2014 Document type: Article Affiliation country: Países Bajos

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2014 Document type: Article Affiliation country: Países Bajos